Edition:
United States

Iovance Biotherapeutics Inc (IOVA.OQ)

IOVA.OQ on NASDAQ Stock Exchange Global Market

9.05USD
15 Dec 2017
Change (% chg)

$0.90 (+11.04%)
Prev Close
$8.15
Open
$8.15
Day's High
$9.50
Day's Low
$8.15
Volume
1,940,063
Avg. Vol
129,916
52-wk High
$9.50
52-wk Low
$4.45

Latest Key Developments (Source: Significant Developments)

Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates
Wednesday, 13 Dec 2017 07:05am EST 

Dec 13 (Reuters) - Iovance Biotherapeutics Inc ::IOVANCE BIOTHERAPEUTICS ANNOUNCES MANUFACTURING DECISION, PROVIDES CLINICAL UPDATES AND HIGHLIGHTS PIPELINE EXPANSION AT ANALYST DAY 2017.IOVANCE BIOTHERAPEUTICS - SELECTED ITS GEN 2 MANUFACTURING PROCESS FOR ALL THREE PHASE 2 TRIALS, ALL FUTURE TIL CLINICAL DEVELOPMENT.IOVANCE - PROTOCOLS FOR 3 EXISTING STUDIES HAVE BEEN AMENDED TO ALLOW ENROLLMENT OF NEW PATIENTS WITH TIL MANUFACTURED WITH GEN 2 PROCESS.IOVANCE - COHORT 1 OF C-144-01 MELANOMA STUDY WILL BE CLOSED AND NEW PATIENTS WILL BE ENROLLED IN COHORT 2.IOVANCE - PHASE 2 STUDY IN PD-1 AND PD-L1 NAÏVE NSCLC PATIENTS WILL INITIATE IN H1 2018.IOVANCE - MD ANDERSON CANCER CENTER TO INITIATE 2 BASKET STUDIES IN SARCOMA & PLATINUM RESISTANT OVARIAN CANCER.IOVANCE - CO RETAINS RIGHTS TO MDA PRECLINICAL RESEARCH IN EXPANDING UNDERSTANDING OF TIL, RELATED INTELLECTUAL PROPERTY.  Full Article

Biolife Solutions Executes Supply Agreement With Iovance Biotherapeutics
Wednesday, 13 Dec 2017 06:30am EST 

Dec 13 (Reuters) - Biolife Solutions Inc ::BIOLIFE SOLUTIONS EXECUTES SUPPLY AGREEMENT WITH IOVANCE BIOTHERAPEUTICS.BIOLIFE SOLUTIONS - EXECUTED AGREEMENT TO SUPPLY CRYOSTOR CELL FREEZE MEDIA AND HYPOTHERMOSOL STORAGE AND SHIPPING MEDIA TO IOVANCE BIOTHERAPEUTICS.  Full Article

Iovance Biotherapeutics reports Q3 GAAP loss per share $0.35
Tuesday, 31 Oct 2017 04:01pm EDT 

Oct 31 (Reuters) - Iovance Biotherapeutics Inc :Iovance Biotherapeutics Inc reports third quarter 2017 financial results.Q3 non-GAAP loss per share $0.31.Q3 GAAP loss per share $0.35.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Iovance Biotherapeutics Inc - ‍anticipates cash, cash equivalents and short-term investments as of December 31, 2017, to be in excess of $141.0 million​.  Full Article

Iovance Biotherapeutics announces pricing of its public offering of $50 mln of common stock
Wednesday, 20 Sep 2017 06:07pm EDT 

Sept 20 (Reuters) - Iovance Biotherapeutics Inc :Iovance Biotherapeutics, Inc. announces pricing of its public offering of $50 million of common stock.Iovance Biotherapeutics- Announced pricing of underwritten public offering of 7.7 million shares of common stock at public offering price of $6.50/share.  Full Article

Iovance BioTherapeutics plans to offer $50 mln of common stock​
Tuesday, 19 Sep 2017 04:35pm EDT 

Sept 19 (Reuters) - Iovance Biotherapeutics Inc :Intends to offer and sell $50 million of its common stock​.Intends to use proceeds from this offering to fund its ongoing clinical trials for its current candidates​.  Full Article

Iovance Biotherapeutics announces approval of 1st clinical trial of LN-145 for treating cervical cancer
Wednesday, 13 Sep 2017 08:00am EDT 

Sept 13 (Reuters) - Iovance Biotherapeutics Inc :Iovance Biotherapeutics announces approval of first clinical trial application by competent authority in Netherlands for a phase 2 trial of LN-145 for the treatment of patients with cervical cancer.  Full Article

Iovance Biotherapeutics enters into a research collaboration with the Ohio State University Comprehensive Cancer Center
Thursday, 7 Sep 2017 08:00am EDT 

Sept 7 (Reuters) - Iovance Biotherapeutics Inc :Iovance Biotherapeutics enters into a research collaboration focused on hematologic malignancies with the Ohio State University Comprehensive Cancer Center.‍Collaboration will initially focus on hematologic malignancies in areas of poor prognostic cancers​.  Full Article

Iovance Biotherapeutics announces FDA fast track designation for LN-144 for treatment of advanced melanoma
Thursday, 31 Aug 2017 04:47pm EDT 

Aug 31 (Reuters) - Iovance Biotherapeutics Inc :Iovance Biotherapeutics announces FDA fast track designation for LN-144 for treatment of advanced melanoma.  Full Article

Iovance Biotherapeutics loss $0.32/shr
Tuesday, 1 Aug 2017 04:01pm EDT 

Aug 1 (Reuters) - Iovance Biotherapeutics Inc :Iovance Biotherapeutics reports second quarter 2017 financial results.Q2 non-GAAP loss per share $0.32.Q2 GAAP loss per share $0.37.Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.  Full Article

Iovance Biotherapeutics Inc - appointed Franco Valle as interim principal financial officer of company
Thursday, 27 Jul 2017 04:52pm EDT 

July 27 (Reuters) - Iovance Biotherapeutics Inc :Iovance Biotherapeutics Inc - on July 26 company appointed Franco Valle to serve as interim principal financial officer of company.  Full Article

BRIEF-Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates

* IOVANCE BIOTHERAPEUTICS ANNOUNCES MANUFACTURING DECISION, PROVIDES CLINICAL UPDATES AND HIGHLIGHTS PIPELINE EXPANSION AT ANALYST DAY 2017